Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models

Lisa Shubitz, Hien T. Trinh, John N Galgiani, Maria L. Lewis, Annette W. Fothergill, Nathan P. Wiederhold, Bridget M. Barker, Eric R G Lewis, Adina L. Doyle, William J. Hoekstra, Robert J. Schotzinger, Edward P. Garvey

Research output: Contribution to journalArticle

28 Scopus citations


Coccidioidomycosis, or valley fever, is a growing health concern endemic to the southwestern United States. Safer, more effective, and more easily administered drugs are needed especially for severe, chronic, or unresponsive infections. The novel fungal CYP51 inhibitor VT-1161 demonstrated in vitro antifungal activity, with MIC50 and MIC90 values of 1 and 2 μg/ml, respectively, against 52 Coccidioides clinical isolates. In the initial animal study, oral doses of 10 and 50 mg/kg VT-1161 significantly reduced fungal burdens and increased survival time in a lethal respiratory model in comparison with treatment with a placebo (P

Original languageEnglish (US)
Pages (from-to)7249-7254
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Issue number12
StatePublished - Dec 1 2015


ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Shubitz, L., Trinh, H. T., Galgiani, J. N., Lewis, M. L., Fothergill, A. W., Wiederhold, N. P., Barker, B. M., Lewis, E. R. G., Doyle, A. L., Hoekstra, W. J., Schotzinger, R. J., & Garvey, E. P. (2015). Evaluation of VT-1161 for treatment of coccidioidomycosis in murine infection models. Antimicrobial Agents and Chemotherapy, 59(12), 7249-7254. https://doi.org/10.1128/AAC.00593-15